For the quarter ending 2025-09-30, SNDX made $45,871,000 in revenue. -$60,715,000 in net income. Net profit margin of -132.36%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 45,871,000 | 37,958,000 | - | 3,726,666.667 |
| Selling, general and administrative | - | - | - | 30,219,750 |
| Cost of product sales | 2,100,000 | 1,279,000 | - | 206,500 |
| Research and development | 56,280,000 | 62,227,000 | - | 56,892,000 |
| Selling, general and administrative | 44,917,000 | 43,805,000 | - | - |
| Total operating expenses | 103,297,000 | 107,311,000 | 0 | 87,091,666.667 |
| Loss from operations | -57,426,000 | -69,353,000 | 0 | -83,365,000 |
| Royalty interest expense | 8,283,000 | 7,854,000 | - | - |
| Other expense | - | 586,000 | - | - |
| Other interest expense | 0 | 4,000 | - | 1,635,333.333 |
| Interest income | 5,269,000 | 5,950,000 | - | 6,882,666.667 |
| Other (expense) income | -275,000 | - | - | -93,000 |
| Total other (expense) income, net | -3,289,000 | -2,494,000 | - | 5,154,333.333 |
| Net loss | -60,715,000 | -71,847,000 | - | -78,210,666.667 |
| Earnings per share, basic, total | -0.7 | -0.83 | -0.98 | -0.913 |
| Earnings per share, diluted, total | -0.7 | -0.83 | -0.98 | -0.913 |
| Weighted average number of shares outstanding, basic, total | 86,620,992 | 86,337,237 | 86,171,889 | 62,832 |
| Weighted-average number of common shares used to compute net loss per share attributable to common stockholdersdiluted | 86,620,992 | 86,337,237 | 86,171,889 | 62,832 |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)